Clozapine Sensors for Improving Therapeutic Treatments of Schizophrenia

用于改善精神分裂症治疗的氯氮平传感器

• 批准号: 8200324
• 负责人: Karen Wu
• 金额: $ 32.86万
• 依托单位: LUCERNA, INC.
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-01 至 2013-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8200324
• 关键词: Accounting; Adverse effects; Adverse reactions; Advocate; Affect; Age; Ambulatory Care; American; Antipsychotic Agents; Binding; Blood; Brain Diseases; Chronic; Clozapine; Detection; Development; Devices; Dose; Drops; Drug Monitoring; Dyes; Ensure; Fluorescence; Goals; High Pressure Liquid Chromatography; Home environment; Incidence; Kinetics; Legal patent; Life; Marketing; Measures; Metabolism; Methods; Monitor; Patients; Pharmaceutical Preparations; Phase; Physicians' Offices; Plasma; Population; Pregnancy Tests; Process; Protocols documentation; Psyche structure; Psychiatrist; RNA; RNA library; Refractory; Resistance; Rights; Risk; Saliva; Sampling; Schizophrenia; Sensitivity and Specificity; Small Business Innovation Research Grant; Specificity; Technology; Testing; Therapeutic; Time; Toxic effect; Treatment Efficacy; Treatment outcome; Universities; Validation; Variant; aptamer; atypical antipsychotic; base; burden of illness; combinatorial; compliance behavior; diet compliance; dosage; health disparity; improved; instrumentation; nanodevice; phase 1 study; phase 2 study; prevent; prototype; rapid technique; research study; sensor; small molecule; technology development; tool

DESCRIPTION (provided by applicant): Schizophrenia is a chronic and debilitating brain disorder that affects about 1.1 percent of the US population age 18 and older in a given year and account for 5% of all disease burden in the US. It is estimated that 20% to 60% of patients have treatment-resistant schizophrenia. Clozapine remains the only effective antipsychotic for treatment-resistant schizophrenia despite the risks of toxic side effects. The toxicities of clozapine are difficult to manage, in part, because of the high interpersonal variability and unpredictability in clozapine metabolism. Thus, therapeutic drug monitoring of plasma drug concentrations through dose adjustments has been advocated in order to increase the use of clozapine, improve clozapine treatment outcome, and prevent potential life- threatening side effects. Using a patented sensor development technology developed by Lucerna founders, we will develop small portable devices for rapid, non-invasive, and inexpensive detection of clozapine and its pharmacologically active metabolite, norclozapine, levels in saliva. This device will allow clozapine dosage to be carefully titered to ensure that patients maintain a therapeutic and safe clozapine level. This phase I SBIR application describes proof-of-concept experiments for developing, characterizing, and optimizing the sensitivity, selectivity, and kinetics of a clozapine- sensing nanodevice. Successful completion of phase I will support our core hypothesis and leads to Phase II experiments that involve adapting the clozapine-sensing nanodevice to a portable readout platform and assessing the prototype sensor device against current methods of clozapine detection and validation according to FDA standards. The resulting product has a high potential for user acceptance in key segments in the therapeutic drug monitoring market such as homes, psychiatrist's offices, and outpatient care facilities. ! PUBLIC HEALTH RELEVANCE: It is estimated that about one million Americans have treatment-resistant schizophrenia, for which clozapine is the most effective antipsychotic drug. However, high interpersonal variability and unpredictability in clozapine metabolism, as well as toxic side effects make doctors reluctant to prescribe this otherwise remarkably effective medication. We will develop a sensitive and simple clozapine-sensing nanodevice that will facilitate routine therapeutic drug monitoring, enabling optimized dosing and efficacy for this important antipsychotic drug. !

描述（由申请人提供）：精神分裂症是一种慢性、使人衰弱的脑部疾病，在特定年份影响 18 岁及以上美国人口的 1.1%，占美国所有疾病负担的 5%。据估计，20%至60%的患者患有难治性精神分裂症。尽管存在毒副作用的风险，氯氮平仍然是治疗难治性精神分裂症唯一有效的抗精神病药物。氯氮平的毒性难以控制，部分原因是氯氮平代谢存在高度的人际差异和不可预测性。因此，提倡通过剂量调整来监测血浆药物浓度的治疗药物，以增加氯氮平的使用，改善氯氮平的治疗结果，并预防潜在的危及生命的副作用。利用 Lucerna 创始人开发的专利传感器开发技术，我们将开发小型便携式设备，用于快速、非侵入性且廉价地检测唾液中氯氮平及其药理活性代谢物去甲氯氮平的水平。该装置将允许仔细滴定氯氮平剂量，以确保患者维持治疗和安全的氯氮平水平。该 I 期 SBIR 应用描述了用于开发、表征和优化氯氮平传感纳米器件的灵敏度、选择性和动力学的概念验证实验。第一阶段的成功完成将支持我们的核心假设，并导致第二阶段实验，其中包括将氯氮平传感纳米设备适应便携式读出平台，并根据 FDA 标准根据当前的氯氮平检测和验证方法评估原型传感器设备。由此产生的产品在治疗药物监测市场的关键领域（例如家庭、精神科医生办公室和门诊护理设施）具有很高的用户接受潜力。 ！ 公共卫生相关性：据估计，约有一百万美国人患有难治性精神分裂症，氯氮平是最有效的抗精神病药物。然而，氯氮平代谢的高度人际差异和不可预测性以及毒副作用使得医生不愿意开这种原本非常有效的药物。我们将开发一种灵敏且简单的氯氮平传感纳米装置，该装置将有助于常规治疗药物监测，从而优化这种重要抗精神病药物的剂量和疗效。 ！